Pfizer Clinical Research Unit - New Haven
New Haven, Connecticut, 06511, United States
NCT Number: NCT06466473
The purpose of this study is to understand how the different formulation of phenytoin is taken up into the blood in Healthy Adults.
This study is seeking healthy adult participants. All the study participants will receive Phenytoin 50 mg chewable tablets manufactured at Ascoli and Vega Baja manufacturing site.
We will measure how the phenytoin will be taken up into the blood in Healthy Adults following oral dosing of Phenytoin.
This will help us determine if the Phenytoin 50 mg chewable tablets manufactured at Ascoli and Vega Baja manufacturing site are similar or not.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
New Haven, Connecticut, 06511, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Phenytoin 50mg chewable tablets
Phenytoin 50mg chewable tablets
Time frame: 72 hours
Time frame: 72 hours
Time frame: Baseline, up to 35 days post last dose.
Pfizer
Industry
A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, 2-WAY CROSSOVER, PIVOTAL BIOEQUIVALENCE STUDY COMPARING 50-MG CHEWABLE DILANTIN® INFATABS® MANUFACTURED AT VEGA BAJA (PUERTO RICO) AND ASCOLI (ITALY) IN HEALTHY ADULT PARTICIPANTS UNDER FASTING CONDITIONS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07689084
Brain Diseases, Central Nervous System Diseases
Marburg, Hesse, Germany
View Trial DetailsNCT06847152
Brain Diseases, Central Nervous System Diseases
Chambéry, Savoie, France
View Trial DetailsNCT05171725
Alzheimer Disease, Brain Diseases
Athens, Greece
View Trial DetailsNCT04266041
Behavior, Brain Diseases
Lebanon, New Hampshire, United States
View Trial Details